Marketresearchnews

Monday, 1 March 2021

Egg Allergy Market 2020 - Opportunity, Driving Trends And Deep Study 2023

The Global Egg Allergy Market is expected to register a CAGR of 7.10%and is anticipated to reach USD 2304.3 Million by 2023. Egg allergies are the most common food allergies. Symptoms of egg allergy can occur immediately or within a few minutes or a few hours. Egg allergy can affect infants as well as adults. The adverse effects of egg allergy can vary from hives or rashes to a severe allergic reaction known as anaphylaxis. Egg allergy happens when there is an overreaction to eggs by the immune system. The immune system identifies egg proteins as harmful and triggers an allergic reaction.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4734

The increasing prevalence of egg allergy and improved allergy diagnosis are the major drivers propelling market growth. However, the lack of awareness in developing countries and high cost constrain the growth of the market.

Market Dynamics

The continued growth in several egg allergy patients is responsible for the increasing demand for required diagnostic tests and medication such as epinephrine autoinjectors, and ultimately, it is propelling the growth of the market. For instance, according to the report published by, McGill University in 2016, egg allergy is common in infants and young children and affects 1 to 2% of the preschool children. Additionally, improved allergy diagnosis is likely to support market growth. On the other hand, the lack of awareness in developing countries and high cost is anticipated to hamper the market growth.

Segmentation

The global egg allergy market has been segmented into age type, diagnosis & treatment, and end user. By age type, the market has been segmented into children and adults. The global egg allergy market has two primary sides—diagnosis & treatment. The global egg allergy market, by diagnosis, has been segmented into skin test, blood test, food challenge, and others. The global egg allergy market, by treatment, has been segmented into medication and oral immunotherapy. By end-user, the market has been segmented into hospitals and clinics, diagnostic centers, research institutes, and others. The hospitals and clinics segment accounted for a market value of USD 729.2 million in 2017.

Key Players

The prominent players in the global egg allergy market are Sanofi SA (France), Genentech, Inc. (the US), Quest Diagnostics (US), ImmuneTech (US), HYCOR Biomedical (US), Kaleo, Inc. (the US), Alletess Medical Laboratory (US), Creative Diagnostics (US), Imutest Ltd (UK), Mylan NV (US), and Impax Laboratories (US).

Some of the key strategies followed by the players operating in the global egg allergy market were innovation, product development, acquisition, and expansion.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/egg-allergy-market-4734

About Us:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Tissue Microarray Market Size And Key Trends In Terms Of Volume And Value 2023

The Global Tissue Microarray Market is expected to register a CAGR of 10.54% and is anticipated to reach USD 10,914.54 million by 2023. Tissue microarrays are paraffin blocks that are created by separating cylindrical tissue cores from different paraffin donor blocks and re-embedding these into a microarray at defined array coordinates. With the help of tissue microarray, up to at least 1000 tissue samples can be arrayed into a single paraffin piece. It allows simultaneous analysis of molecules present in DNA, mRNA, and protein levels under identical, standardized conditions on a single glass slide. This adaptable strategy, in which data analysis is automated, facilitates retrospective and prospective human tissue studies.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1213

The increasing application in drug discovery, increasing prevalence of cancer, growing advancements in biotechnology and pharmaceutical companies, and rising demand for cost-effective and accurate diagnostic methods are the major drivers propelling market growth. However, tissue microarray may not be fruitful for heterogeneous cancers, which is likely to constrain the growth of the market.

Market Dynamics

The prevalence of cancer is one of the crucial factors that drive the growth of the tissue microarray market. According to the American Cancer Society, in 2017, nearly 13% of all cancers diagnosed in adults aged 20. It further stated that rates of liver cancer, thyroid cancer, and melanoma are increasing from last few years. According to US Breast Cancer Statistics, about 1 in 8 US women (about 12%) will develop invasive breast cancer throughout their lifetime. In 2017, an estimated 252,710 new cases of invasive breast cancer were expected to be diagnosed in women in the US, along with 63,410 new cases of non-invasive (in-situ) breast cancer.

Moreover, increasing advancements in biotechnology and pharmaceutical companies and growing demand for cost-effective and accurate diagnostic methods have fueled the growth of the market. On the other hand, tissue microarray is that it may not be fruitful for heterogeneous cancers anticipated to hamper the market growth.

Segmentation

The global tissue microarray market has been divided into the procedure, technology, application, and end user. By procedure, the market has been segregated into immunohistochemistry, fluorescent in-situ hybridization, and frozen tissue array. Based on technology, the market has been segmented into DNA microarray, polymerase chain reaction (PCR), next-generation sequencing, northern blotting, and western blotting. Based on the application, the market has been bifurcated into oncology, gene expression profiling, SNP detection, double-stranded B-DNA microarrays, comparative genomic hybridization, and sequencing bioinformatics. By end-user, the market has been classified as pharmaceutical and biotechnological companies and research organization. The research organization segment accounted for a market value of USD 1876.02 million in 2016.

Key Players

The prominent players in the global tissue microarray market are Agilent Technologies, Illumina, Inc., Protein Biotechnologies Inc., Asterand Bioscience, Pantomics Inc., Applied Microarrays, Arrayit, Phalanx Biotech, QIAGEN, Takara Bio, Perkin Elmer, and Merck Sharp & Dohme Corp.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/tissue-microarray-market-1213

About Us:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Friday, 26 February 2021

Paresthesia Treatment Market To Show Steady Growth, 2023

Paresthesia is an abnormal sensation of the skin such as numbness, burning, pricking, and many other. On the basis of severity, they are acute or chronic. Some of the major causes of for the diseases are vitamin deficiency, hyperventilation syndrome, or by the use of anesthesia. The global paresthesia treatment market is majorly driven by increasing prevalence of the paresthesia, changing lifestyle and poor diet. Furthermore, development in the healthcare expenditure, the government support for the research & development for new and better treatment have fuelled the market growth. However, lack of effectiveness and unavailability of precise treatment may hinder the market growth over the forecasted period.

Global Paresthesia Treatment market is expecting a healthy growth at a CAGR of 7.2 % during the forecast period 2017-2013.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/719

Segmentation

The global paresthesia treatment market is segmented on the basis of types, treatments, and end users. On the basis of types, the market is segmented into acute paresthesia, chronic paresthesia. On the basis of treatment, the market is segmented into immunosuppressant, anticonvulsants, topical creams, antivirals, and others. Immunosuppressant is further classified into prednisone, intravenous gamma globulin, and others. Topical creams are further classified into lidocaine, prilocaine, and other. On the basis of end users the market is segmented into hospitals, clinics, diagnosis centers, and others.

Regional analysis

America dominates the global paresthesia treatment market owing to the presence of a large number of patients with paresthesia and well developed technology. Furthermore, the government support for the research & development, and high healthcare expenditure have supported the growth of the market. Europe accounts for the second largest market, which is followed by Asia Pacific. Asia Pacific is the fastest growing market due to the presence of the huge opportunities in the market. India and China is the major contributor to the market owing to the presence of huge population base and rapidly growing economies. The Middle East & Africa holds the lowest share in the market.

Key players

Some of the major players in the global paresthesia treatment market are Medtronic (UK), Omron Healthcare, Inc. (US), Boston Scientific Corporation (US), Stimwave LLC, (US), Nevro Corp. (US), Cyberonics, Inc. (US), EnteroMedics Inc. (US), St. Jude Medical, LLC. (US), Bio-Medical Research Ltd. (UK), Baxter (US), Stryker (US), GlaxoSmithKline plc.(UK).

Browse more details of Report @ https://www.marketresearchfuture.com/reports/paresthesia-treatment-market-719

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Protein Engineering Market 2020 - Opportunity, Driving Trends And Deep Study 2024

Proteins, the building blocks of the body, are large biomolecules made up of amino acids. They perform various functions such as DNA replication, catalyzing metabolic reactions, transporting molecules from one location to another, and responding to stimuli. Furthermore, proteins also have a wide range of applications in the diagnosis of disease and treatment development. Protein engineering involves designing and constructing new proteins by modifying amino acid sequences to produce enzymes and desired properties and the synthesis of proteins with a particular structure. This technology helps us to understand the basics of how enzymes function and have evolved, and it is the key method of improving enzyme properties for applications in pharmaceuticals, green chemistry, and biofuels.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/691

The major objective of protein engineering is to produce biological compounds which include a synthetic peptide, storage protein, and synthetic drugs which will be superior to a normal one and create an enzyme which is superior in its properties to produce high-value chemicals in large quantities.

The global protein engineering market is driven by the increasing demand for new technologies having their application in healthcare and by the growth in research and development activities for improving health outcomes using novel technologies. Furthermore, the emergence of trends in protein identification and tracking and the increasing use of protein studies in research activities drive the growth of this market. However, there are various factors that may hinder the growth of the market such as expensive instruments used in protein engineering that require huge maintenance and lack of trained personnel.

Global market for protein engineering is expected to grow at a CAGR of approximately 6.2% during the forecast period 2017–2023.

Segmentation:

The global protein engineering market is segmented to the basis of type, method, application, and end-users.

On the basis of type, the market is segmented into instrument, reagents, and services and software.

On the basis of method, the market is segmented into rational protein design and directed evolution.

On the basis of application, the market is segmented into food and detergent industries, environment applications, medical applications, biopolymer production, and nanobiotechnology.

On the basis of end-user, the market is segmented into academic research institutes, pharmaceuticals and biotechnology companies, and contract engineering organizations.

Regional Analysis

Globally, protein engineering market consists of four regions, namely, Americas, Europe, Asia Pacific, and the Middle East and Africa. North America is the largest market owing to the concentration of major market players and increase in a number of biotechnology and pharmaceutical companies. The U.S. is the largest market in North America followed by Canada. In the U.S., extensive protein engineering technologies and methods and availability of technologically-advanced devices and instruments for research also drive the growth of the market.

Europe is the second largest market for protein engineering which is majorly driven by the increasing demand for protein engineering methods and technologies and the overall growth of research and development sector in major countries such as Germany, the U.K., and France. Furthermore, the growth in funding for protein engineering and emphasis on drug discovery are other factors expected to drive the growth of the market during the review period.

Asia Pacific shows the fastest growth which is driven by the rising prevalence of lifestyle diseases such as heart diseases, diabetes, obesity, and others and need for new technologies with their application in healthcare.

The Middle East and Africa shows a steady but positive growth with an increase in the demand for new drugs and devices for diagnosis and the treatment of diseases and improvement in healthcare infrastructure.

Key Players

Agilent Technologies (U.S.), AB-Sciex (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Bruker Corp. (U.S.), GE Healthcare (U.K.), Perkin Elmer (U.S.), Sigma-Aldrich Corp. (U.S.), Thermo Fisher Scientific (U.S.), and Waters Corp. (U.S).

Browse more details of Report @ https://www.marketresearchfuture.com/reports/protein-engineering-market-691

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Orthopedic Biomaterial Market 2020 - Current And Future Plans 2023

Orthopedic biomaterials are synthetic or organic materials. They are used for internal fracture fixation. Orthopedic biomaterials are commonly used in orthopedics, surgical implants, prosthetics, and various medical tools and devices.

The global orthopedic biomaterial market is majorly driven by the increasing older population leading to increase in the patient population, increasing surgeries, the various government supports, and growing awareness among young population towards health.

According to the United Nations, approximately over 962 million people were aged over 60 and above globally in 2017. The United Nations has also estimated that by 2050, the number of older population is likely to reach 425 million. This increasing aging population is likely to boost the growth of the global orthopedic biomaterial market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/415

Factors such as rigorous clinical and regulatory processes are likely to hamper the growth of the orthopedic biomaterial market.

Global orthopedic biomaterial market is expected to grow at a CAGR of 10.5% during the forecast period.

Segments

The global orthopedic biomaterials market is segmented on the basis of types of material, application, and end-user.

On the basis of types of material, the market is segmented into metals and non-metals. The metals are further sub-segmented into titanium alloy, stainless steel, cobalt alloy, and others. Non-metals are further sub-segmented into polymeric, natural biomaterials, ceramic, and others. Ceramics are sub-segmented into alumina, zirconium dioxide, calcium phosphate, carbon, and others. Polymeric materials are sub-segmented into polyester, silicone, polyethylene, polymethylmethacrylate (PMMA), and others. Natural biomaterials are sub-segmented into chitin and chitosan, collagen, and others.

On the basis of application, the market is segmented into joint replacement, spine implants, fracture fixation devices, tissue fixation, viscosupplementation, and others. Joint replacement is sub-segmented into shoulder and elbow replacement, hip replacement, knee replacement, and others. Tissue fixation is sub-segmented into suture anchors, interference screws, and others. The fracture fixation devices are sub-segmented into screws, plates for bones, rods, and others.

On the basis of end-user, the market is segmented into hospitals, clinics, and others.

Regional Analysis

The North American orthopedic biomaterial market is a growing market in the Americas region. On a regional basis, the Americas region is segmented into North America and South America. North America is segmented into the U.S. and Canada. The increasing prevalence of different orthopedic surgeries, along with the increasing older population eventually leading to an increase in patient population is likely to drive the market. Additionally, increasing awareness of biodegradable products among the people, growing healthcare expenditure, and the rising demand for technologically advanced treatments and products along with rising the government support are likely to enhance the growth of the orthopedic biomaterial market in North America. For instance, according to the American Joint Replacement Registry, around 1,61,040 joint replacement procedures took place in the U.S. in 2016.

Europe is the second largest market and holds a strong share in the global orthopedic biomaterial market. The European market is expected to grow during the forecast period owing to the availability of innovative treatment facilities and rising research activities in orthopedic biomaterials for nanotechnology. Furthermore, increasing cases in orthopedic surgeries along with the rising population awareness regarding health is driving the growth of the orthopedic biomaterial market.

Asia Pacific is expected to be the fastest growing market. The increasing prevalence of chronic diseases is the major driver of market growth. China is the fastest growing region owing to an increasing population leading to rising patient population. Rising awareness about health and availability of new treatment methods drive the market in this region. Rising healthcare expenditure and the rise in the standard of living are driving the growth of the orthopedic biomaterial market in the Asia Pacific region.

The Middle East and Africa is expected to show the least growth in the market due to some major factors such as lack of awareness, limited access, and availability of treatment facilities. In the Middle East, the United Arab Emirates is the largest market, owing to the rising healthcare expenditure and the overall growth of the healthcare scenario also drives the market.

Key Players

Some of the key players in the orthopedic biomaterial market are CoorsTek Inc., CERADYNE, Straumann, Stryker, Kyocera Corporation, Materion Corporation, 3M ESPE, Nobel Biocare Services AG, Morgan Advanced Materials, and DePuy Synthes.

Browse more details of Report @ https://www.marketresearchfuture.com/reports/orthopedic-biomaterial-market-415

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Hematocrit Test Market Segments, Opportunity, Growth And Forecast By End-Use Industry 2023

Also known as packed-cell volume (PCV) test, hematocrit test is used to measure the percentage of Red Blood Cells (RBCs) in the blood. The major function of the RBCs is to carry blood throughout the body. The test is usually performed to diagnose various diseases such as anemia, leukemia, lymphoma, congenital heart disease, and others. The test determines the elevation in the percentage of normal RBCs which is 38.8%-50% in men and 34.9%-44.5% in women. The hematocrit test is one of the tests included under complete blood count (CBC) test.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5553

Cardiovascular diseases, cancer, and kidney diseases are increasing the economic burden of various developing and developed nations across the globe. The market for hematocrit test is driven by rising prevalence of chronic diseases such as cardiovascular diseases, diabetes, and others along with changing lifestyle, and increasing demand for diagnostic devices for cardiovascular diseases. However, limited number of trained personnel has restrained the growth of the market. However, the high cost of diagnosis and treatment of cardiovascular diseases also restrains the growth of the market. As per the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the overall prevalence of Chronic Kidney Disease (CKD) in the general population across the globe is nearly 14%. However, the growth of the market is restrained by the inaccurate or misleading result of the test and unawareness about hematocrit test in the diagnosis of the disease.

The global hematocrit test market is expected to grow at a CAGR of 4.5% during the forecast period.

Segments

The global hematocrit test market is segmented on the basis of product, indication, devices, and end-user.

On the basis of product, the market is segmented into the analyzer, hematocrit test meter, and others.

On the basis of indication, the market is segmented into anemia, leukemia, lymphoma, congenital heart disease, kidney tumor, and others.

On the basis of the end-user, the market is segmented into hospitals & clinics, diagnostic centers, and others.

Intended Audience

Medical Device Manufacturers
Medical Device Suppliers
Medical Research Laboratories
Research and Development (R&D) Companies
Market Research and Consulting Service Providers
Potential Investors

Regional Analysis of the Global Hematocrit Test Market

The global hematocrit test market consists of four major regions namely, the Americas, Europe, Asia Pacific and the Middle East & Africa, with the Americas capturing the largest market share. The growth of the market is attributed to an increase in the demand for diagnostic procedures, and rising importance of hematology testing for the diagnosis of various chronic diseases. North America accounts for the major share in the American hematocrit test market which is attributed to extensive use of hematocrit test with other diagnostic tests. According to the Center for the Disease Control and Prevention (CDC), as of 2012, nearly half of all the adults, 117 million population in the U.S. had one or more chronic health conditions. One in four adults were diagnosed with two or more chronic health diseases.

In Europe, the growth of the market is driven by increasing demand for diagnostic devices and instrument in hospitals and diagnostic centers. Germany, the U.K, and France are the major contributors to the growth of the market owing to an increase in the number of key players engaged in the manufacturing of medical devices and instruments and rising expenditure in research and development by these major economies. Additionally, well-developed healthcare sector, ever-increasing patient population and high healthcare expenditure by the European nations fuel the market growth.

The Asia Pacific is expecting the fastest growth in the market due to the flourishing growth of healthcare industries in developing economies such as India. Additionally, the ever-increasing prevalence of kidney diseases and cardiovascular diseases and rising demand for quality devices in the healthcare sector is expected to lead the use of advanced equipment, which, in turn, may speed up the market growth in the region. Rising geriatric population with chronic diseases further creates the economic burden on the developing nations thereby accelerating the market growth.

The Middle East & Africa hold the least share in the market. The market in this regions exhibits steady growth owing to an increase in the demand for the diagnostic and treatment services. In the Middle East and Africa, the United Arab Emirates (UAE) hold the largest market share owing to the availability of diagnostic and treatment services. Africa shows slow growth due to low technology penetration in developing countries.

Key Players in the Global Hematocrit Test Market

Some of the key players in this market are Abbott (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Siemens AG (Germany), Beckman Coulter, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Horiba, Ltd. (Japan), Mindray Medical International Limited (China), Boule Diagnostics AB (Sweden), Nihon Kohden Corporation (Japan), Sysmex Corporation (Japan), and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/hematocrit-test-market-5553

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Dravet syndrome Market, Segments, Growth And Value Chain Analysis 2023

Dravet syndrome is a rare genetic epileptic encephalopathy that begins during the first year of life in an otherwise healthy infant. According to the National Center for Advancing Translational Sciences, in 15% to 25% cases of the Dravet syndrome, a family history of epilepsy or febrile seizures exists. It is also reported that 85% cases of Dravet syndrome originated due to a mutation in the SCN1A gene.

It is noted that development of new drugs and therapies, and rising R&D expenditure are propelling the growth of the market. In recent years, Dravet syndrome has gained significant attention due to the upcoming drugs for its treatment. For instance, on February 06, 2018, Zogenix, Inc. received breakthrough therapy designation from FDA for its product, ZX008. The drug is specialized for the treatment of Dravet syndrome and its related complications.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/5509

Various other factors such as unmet medical needs, increasing government assistance, rising healthcare expenditure in the developed countries, improving regulatory framework, increasing adoption rate, and rising funding and reimbursement policies are continuously contributing to the growth of the global Dravet syndrome market.

Despite these drivers, there are some issues associated with Dravet syndrome market. The side effects of drugs and other therapeutic agents, lack of awareness in the developing countries, and poor healthcare system in low and middle-income countries, may hinder the growth of the market.

It is estimated that the Dravet syndrome market is expected to grow at a CAGR of 8.5% during the forecast period of 2017-2023.

Intended Audience:

Pharmaceutical Companies
Research and Development (R&D) Companies
Government Research Institute
Academic Institutes and Universities

Key Players:

Some of key the players in the global dravet syndrome market are Biocodex, Biscayne Neurotherapeutics, Cyberonics, Inc., Epygenix Therapeutics, Inc., GW Pharmaceuticals, plc, INSYS THERAPEUTICS, INC., OPKO Health Inc., Ovid Therapeutics, PTC Therapeutics, Sage Therapeutics, Takeda Pharmaceutical Company Limited, Thermo Fisher Life Technologies, Xenon Pharmaceuticals, Zogenix, Inc, and others.

Segmentation:

The global Dravet syndrome market is segmented on the basis of the type of seizures, diagnosis, treatment & management, and end-user.

On the basis of the type of seizures, the market is classified as myoclonic seizures, atonic seizures, partial seizures, absence seizures, tonic clonic seizures, photosensitive seizures, and others.

On the basis of the diagnosis, the market is classified as magnetic resonance imaging (MRI), electroencephalography (EEG), SCN1A testing, and others.

On the basis of the treatment & management, the market is classified as seizure medications, ketogenic diet, vagus nerve stimulation (VNS), and others. The seizure medications segment is further classified into clobazam, stiripentol, sodium valproate, and others.

On the basis of the end-user, the market is segmented into pharmaceutical companies, hospitals, diagnostic laboratories, academic and research institutes, and others.

Browse More Details of the Report @

@ https://www.marketresearchfuture.com/reports/dravet-syndrome-market-5509

About US:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com